Diagnosis and treatment of bacteremia and intravascular catheter infections

American Journal of Surgery

Volumn 172, Issue 6 A, 1996, Pages 13s-19s

  Bullard, Kelli M ^a   Dunn, David L ^b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^c UNIV OF MINNESOTA HOSP AND CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CEPHALOSPORIN DERIVATIVE; PENICILLIN DERIVATIVE;

ANTIBIOTIC RESISTANCE; BACTEREMIA; CATHETER INFECTION; CONFERENCE PAPER; FUNGEMIA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOTHERAPY; INFECTION PREVENTION; INSTRUMENT STERILIZATION; PRIORITY JOURNAL; SEPSIS; STRAIN DIFFERENCE;

EID: 0030476510     PISSN: 00029610     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9610(96)00345-5     Document Type: Conference Paper

References (51)

1. Pittet D, Wenzel RP. Nosocomial bloodstream infections. Arch Intern Med. 1995;155:1177-84.
2. Banerjee SN, Emori TG, Culver TH, et al. Secular trends in nosocomial primary bloodstream infections in the United States, 1980-1989. Am J Med. 1991;91(suppl 3B):86-9.
3. Centers for Disease Control. Increase in national hospital discharge survey rates for septicemia - United States. MMWR. 1990;39:31-4.
4. Burd RS, Cody CS, Dunn DL. Immunotherapy of Gram-Negative Bacterial Sepsis. Austin, TX: Armstrong Printing, 1992.
5. Barie PS. Emerging problems in gram-positive infections in the postoperative patient. Surg Gynecol Obstet. 1993;177:S55-S64.
6. Widmer AF. IV-related infections. In: Wenzel R, ed. Prevention and Control of Nosocomial Infections. Baltimore: Williams and Wilkins; 1993:556-79.
7. Elliott TSJ, Faroqui MH, Armstrong RF, et al. Guidelines for good practice in central venous catheterization. J Hosp Infect. 1994;28:163-76.
8. Whitman ED. Complications associated with the use of central venous access devices. Curr Prob Surg. 1996;33:311-78.
9. Howard RJ. Hospital-acquired infections in surgical patients. In: Howard RJ, Simmons RL, eds. Surgical Infectious Diseases, 3rd ed. Norwalk, CT: Appleton and Lange; 1995:489-90.
10. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med. 1992;20:864-74.
11. Ziegler E, Fisher C, Sprung C, et al. Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. N Engl J Med. 1991;324:429.
12. Greenman R, Schein R, Martin M, et al. A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. The XOMA Sepsis Study Group. JAMA. 1991;266:1097.
13. Fisher CJ, Dhainaut JF, Opal SM, et al. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. JAMA. 1994;271:1836-43.
14. Dunn DL. Gram-negative bacterial sepsis and sepsis syndrome. Surg Clin North Am. 1994;74:621-35.
15. The EORTC International Antimicrobial Therapy Cooperative Group. Ceftazidime combined short or long course of amikacin for empiric therapy of gram-negative bacteremia in cancer patients with granulocytopenia. N Engl J Med. 1987;317:1692-8.
16. Klastersky J, Glauser MP, Schimpff SC, et al. Prospective randomized comparison of three antibiotic regimens for empiric therapy of suspected bacteremic infection in febrile granulocytopenic patients. Antimicrob Agents Chemother. 1986;29:263-70.
17. Jones WG, Barie PS. Enteroccocal infections in surgical patients. Infect Surg. 1988;7:733-8.
18. Jones WG, Barie PS, Yurt RW, Goodwin CW. Enteroccocal burn sepsis: a highly lethal complication in severely burned patients. Arch Surg. 1986;121:649-53.
19. Zervos MJ, Dembinski S, Mikesell T, Schaberg DR. High-level resistance to gentamicin in Streptococcus faecalis: risk factors and evidence for exogenous acquisition. J Infect Dis. 1986;153:1075-83.
20. Zervos MJ, Kauffman CA, Therasse PM, et al. Nosocomial infection by gentamicin-resistant Streptococcus faecalis: an epidemiologic study. Ann Intern Med. 1987;106:687-91.
21. Patterson JE, Zervos MJ. Susceptibility and bacteriocidal activity studies of four β-lactamase producing enterococci. Antimicrob Agents Chemother. 1989;33:251-3.
22. Uttley AH, Collins CH, Naidoo J, George RC. Vancomycin-resistant enterococcus. Lancet. 1988;ii:57-8.
23. Leclercq R, Derlot E, Duval J, Courvalin P. Plasmid-mediated resistance to vancomycin and teicoplanin in Enterococcus faecium. N Engl J Med. 1988;319:157-61.
24. Derlot E, Courvalin P. Mechanisms and implications of glycopeptide resistance in enterococci. Am J Med. 1991;91(suppl 3B):82-5.
25. Rex JH, Bennett JE, Sugar AM, et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. N Engl J Med. 1994;331:1325-30.
26. Maki DG, Weise CE, Sarafin HW. A semi-quantitative culture method for identifying intravenous catheter related infection. N Engl J Med. 1977:296:1305-9.
27. Collignon PJ, Soni N, Pearson IY, et al. Is semi-quantitative culture of central venous catheter tips useful in the diagnosis of catheter associated bacteremia? J Clin Microbiol. 1986;24:532-5.
28. Jones PG, Hopfer RL, Etling L, et al. Semiquantitative cultures of intravascular catheters from cancer patients. Diagn Microbiol Infect Dis. 1986;4:299-306.
29. Flynn PM, Shenep JL, Barrett FF. Differential quantitation with a commercial blood culture tube for diagnosis of catheter-related infection. J Clin Microbiol. 1988;26:1045-6.
30. Mosca R, Curtas S, Forbes B, Meguid MM. The benefits of isolator cultures in the management of suspected catheter sepsis. Surgery. 1987;102:718-23.
31. Raucher HS, Hyatt AC, Barzilai A, et al. Quantitative blood cultures in the evaluation of septicemia in children with broviac catheters. J Pediatr. 1984;104:29-33.
32. Wing EJ, Norden CW, Shadduck RK, Winkelstein A. Use of quantitative bacteriologic techniques to diagnose catheter-related sepsis. Arch Intern Med. 1979;139:482-3.
33. Cobb DK, High KP, Sawyer RG, et al. A controlled trial of scheduled replacement of central venous and pulmonary-artery catheters. N Engl J Med. 1992;327:1062-8.
34. Pettigrew RA, Lang SDR, Haydock DA, et al. Catheter related sepsis in patients on intravenous nutrition: a prospective study of quantitative guidewire changes for suspected sepsis. Br J Surg. 1985;72:52-5.
35. Armstrong CW, Mayhall CG, Miller KB, et al. Prospective study of catheter replacement and other risk factors for infection of hyperalimentation catheters. J Infect Dis. 1986;154:808-16.
36. Shaffer D. Catheter-related sepsis complicating long-term tunneled central venous dialysis catheters: management by guidewire exchange. Am J Kidney Dis. 1995;25:593-6.
37. Nahata MC, King DR, Powel DA. Management of catheter-related infections in pediatric patients. J Parenter Enteral Nutr. 1988;12:58-9.
38. Prince A, Heller B, Levy J, Heind WC. Management of fever in patients with central venous catheters. Pediatr Infect Dis J. 1986;5:20-4.
39. Wang EEL, Prober CG, Ford-Jones L. The management of central intravenous catheter infections. Pediatr Infect Dis J. 1984;3:110-3.
40. Johnson DC, Johnson FL, Goldman S. Preliminary results treating persistent venous catheter infections with the antibiotic lock technique in pediatric patients. Pediatr Infect Dis J. 1994;13:930-1.
41. Early TF, Gregory RT, Wheeler JR, et al. Increased infection rate in double lumen versus single-lumen Hickman catheters in cancer patients. South Med J. 1990;83:34-6.
42. Mermel LA, McCormick RD, Springman SR, et al. The pathogenesis and epidemiology of catheter-related infection with pulmonary artery Swan-Ganz catheters: a prospective study using molecular subtyping. Am J Med. 1991;91 (suppl 3B):197-205.
43. Christensen ML, Hancock ML, Gattuso J, et al. Parenteral nutrition associated with increased infection rate in children with cancer. Cancer. 1993;72:256-63.
44. Wagman LD, Kirkemo A, Johnston MR. Venous access: a prospective randomized study of the Hickman catheter. Surgery. 1984;95:303-8.
45. Andrivet P, Bacquer A, Ngoc CV, et al. Lack of clinical benefit from subcutaneous tunnel insertion of central venous catheters in immunocompromised patients. Clin Infect Dis. 1994;18:34-6.
46. Lim SH, Smith MP, Machin SJ, Goldstone AH. A.prospective randomized study of prophylactic teicoplanin to prevent early Hickman-catheter-related sepsis in patients receiving intensive chemotherapy for haematological malignancies. Eur J Haematol. 1993;54:10-3.
47. Maki DG, Cobb L, Garman JK, et al. An attachable silver-impregnated cuff for prevention of infection with central venous catheters: a prospective randomized multicenter trial. Am J Med. 1988;85:307-14.
48. Flowers RHI, Schwenzer KJ, Kopel RF, et al. Efficacy of an attachable subcutaneous cuff for the prevention of intravascular catheter-related infection: a randomized, controlled trial. JAMA. 1989;261:878-83.
49. Maki DG, Wheeler SJ, Stos SM, Mermel LA. Clinical trial of a novel antiseptic central venous catheter. Program and Abstracts of the 31st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, September 29-October 2, 1991. Washington, DC: American Society for Microbiology, 1991.
50. Applegren P. Does surface heparinization reduce bacterial colonization of central venous catheters? Lancet. 1995;345:130.
51. Fraschini G. Urokinase prophylaxis of central venous ports reduces infections and thrombotic complications. NAVAN Fifth Annual Conference Syllabus. 1991;33.